ArticleOncogene2026
Nuclear cathepsin L induces DNA damage by regulating DNA repair factors in ovarian cancer.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to PARP inhibitors (PARPi) remains a major clinical challenge in ovarian cancer (OC), emphasizing the need for novel strategies to enhance therapeutic efficiency. Our previous work revealed that the antimalarial drug quinacrine (QC) can be repurposed to induce cell death in OC by promoting lysosomal release of active cathepsin L (CTSL). Building on these outcomes, we investigated whether QC-activated CTSL influences DNA damage and homologous recombination (HR) repair in OC cells. Our experimental evidence shows that QC-activated CTSL downregulates key DNA repair proteins RAD51 and 53BP1, leading to impaired HR repair and increased DNA damage. Importantly, genetic knockdown of CTSL significantly reduced QC-induced DNA damage, confirming the CTSL plays a direct functional role in this process. We also found out that the response of combined QC and PARPi differs in models. CTSL was translocated to the nucleus (nCTSL) in responsive patient-derived ascitic (PDA) and patient-derived xenograft (PDX) spheroids. Contrarily, non-responsive models did not have nuclear CTSL. Mechanically, QC could not suppress CRM1/XPO1 nuclear export receptor in non-responsive cells, leading to continued export of CTSL from the nucleus. To address this, we have used the CRM1 inhibitor KPT-8602, which restored nuclear retention of CTSL. This led to enhanced therapeutic synergy with PARPi and overcame resistance in QC-treated PDA 3D-spheroids. Consistent with these findings, QC reduced tumor burden in both the cell-derived OVCAR-5 xenograft and PDX-PH070 models that showed QC-induced nCTSL, but not in the non-responsive PDX-PH095 model. However, in additional non-responsive PDX models (PH747 and PH081), treatment with QC and KPT-8602 substantially reduced tumor burden. Collectively, our results confirm a critical role for nuclear CTSL in QC-induced DNA damage and identify nCTSL as a possible predictive biomarker of therapeutic response. These results suggest that combining QC with PARPi or CRM1 inhibitors represents a promising strategy to overcome PARPi resistance in OC.
Identifiers
42823448What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.